[1]潘铭,顾刚寿,黄建霞,等.髓白1号方辅助化疗治疗急性髓细胞白血病临床研究[J].中国中医药信息杂志,2019,26(3):16-19.[doi:10.3969/j.issn.1005-5304.2019.03.005]
 PAN Ming,GU Gangshou,HUANG Jianxia,et al.Clinical Study on Suibai No.1 Prescription Combined with Chemotherapy for Treatment of Acute Myeloid Leukemia[J].zhongguo zhongyiyao xinxi zazhi,2019,26(3):16-19.[doi:10.3969/j.issn.1005-5304.2019.03.005]
点击复制

髓白1号方辅助化疗治疗急性髓细胞白血病临床研究

参考文献/References:

[1] 李小梅,焦顺昌.哈里森肿瘤学手册[M].北京:科学出版社,2017:693- 694.
[2] 沈梯,赵永强.血液病诊断及疗效标准(第4版)[M].北京:科学出版社, 2018:87-110.
[3] 储大同.当代肿瘤内科治疗方案评价(第3版)[M].北京:北京大学医学出版社,2010:381-382.
[4] 郑莜萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:223-224.
[5] 周际昌.实用肿瘤内科学[M].北京:北京科学技术出版社,2013:445-446.
[6] WEI G, NI W, CHIAO W, et al. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome[J]. J Hematol Oncol,2011,4:46.
[7] JI Q, DING Y H, SUN Y, et al. Antineoplastic effects and mechanisms of micheliolide in acute myelogenous leukemia stem cells[J]. Oncotarget,2016,7(40):65012-65023.
[8] ATTAR E C, JOHNSON J L, AMREIN P C, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502[J]. J Clin Oncol,2013,31(7):923- 929.
[9] COWAN A J, LASZLO G S, ESTEY E H, et al. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin[J]. Front Biosci (Landmark Ed),2013,18:1311-1334.
[10] GANETSKY A. The role of decitabine for the treatment of acute myeloid leukemia[J]. Ann Pharmacother,2012,46(11):1511-1517.
[11] 蔡植华,郑乃莹,柳子川.沙利度胺联合常规化疗治疗急性白血病的疗效观察[J].现代中西医结合杂志,2015,24(15):1631-1633.
[12] GRIFFITHS E A, BRADY W E, TAN W, et al. A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia[J]. Leuk Res,2016,43:44-48.
[13] 杨金坤.现代中医肿瘤学[M].上海:上海中医药大学出版社,2004:428-429.
[14] 黄礼明.白血病的中医药诊治[M].北京:科学出版社,2010:153-155.
[15] 闫理想,史哲新,杨向东,等.益气养阴方对白血病干细胞MDR1 mRNA和P-gp表达的影响[J].中国中西医结合杂志,2017,37(12):1491-1495.
[16] 黄云胜,施志明,丁金芳.益气养阴法对肺癌患者外周血肿瘤免疫逃逸相关因子的影响[J].上海中医药大学学报,2007,21(3):48-51.
[17] 陈智,林圣云,蒋剑平,等.白花蛇舌草对香豆酸组合物对急性髓系白血病细胞Kasumi-1生长抑制作用[J].中国中西医结合杂志,2017, 37(9):1089-1094.(收稿日期:2018-09-30)(修回日期:2018-11-12;编辑:季巍巍)

相似文献/References:

[1]胡玲,周福生,王汝俊,等.《中西医结合研究思路与方法》教学体会[J].中国中医药信息杂志,2007,14(7):106.
 [J].zhongguo zhongyiyao xinxi zazhi,2007,14(3):106.
[2]杨国栋.裴正学中西医结合学术思想与临证特色浅析[J].中国中医药信息杂志,2010,17(5):84.
[3]钱华.中西医结合的难点和方法思考[J].中国中医药信息杂志,2008,15(2):1.
 [J].zhongguo zhongyiyao xinxi zazhi,2008,15(3):1.
[4]岳雯.中西医结合妇产科临床教学改革探索与实践[J].中国中医药信息杂志,2008,15(9):111.
 [J].zhongguo zhongyiyao xinxi zazhi,2008,15(3):111.
[5]焦宁,陈冲,徐瑞荣.益气养阴方及其拆方对急性髓细胞白血病小鼠细胞凋亡及相关蛋白的影响[J].中国中医药信息杂志,2014,21(2):42.[doi:10.3969/j.issn.1005-5304.2014.02.012]
 JIAO Ning,CHEN Chong,XU Rui-rong.Effect of Yiqi Yangyin Recipe and Its Different Assembling on Apoptosis Rate and Expression of Associated Protein in Acute Myeloid Leukemia Mice[J].zhongguo zhongyiyao xinxi zazhi,2014,21(3):42.[doi:10.3969/j.issn.1005-5304.2014.02.012]
[6]周莉,樊永平.中西医结合临床研究生科研能力培养探讨[J].中国中医药信息杂志,2012,19(10):97.[doi:10.3969/j.issn.1005-5304.2012.10.046]
 [J].zhongguo zhongyiyao xinxi zazhi,2012,19(3):97.[doi:10.3969/j.issn.1005-5304.2012.10.046]
[7]卢建新.论外科医生系统学习中医理论和内科临床的必要性[J].中国中医药信息杂志,2014,21(4):102.[doi:10.3969/j.issn.1005-5304.2014.04.034]
 [J].zhongguo zhongyiyao xinxi zazhi,2014,21(3):102.[doi:10.3969/j.issn.1005-5304.2014.04.034]
[8]刘学军.浅谈中西医结合治疗肿瘤的系统观[J].中国中医药信息杂志,2008,15(11):4.
 [J].zhongguo zhongyiyao xinxi zazhi,2008,15(3):4.
[9]伍洪波,张绍金,熊坚.湖南省2001-2004年中西医结合类医师资格实践技能考试考生背景及其考试成绩分析[J].中国中医药信息杂志,2006,13(3):99.
 [J].zhongguo zhongyiyao xinxi zazhi,2006,13(3):99.
[10]魏平,王文君,洪义,等.血液流变学中西医结合文献研究[J].中国中医药信息杂志,1995,2(7):29.

备注/Memo

基金项目:甘肃省自然科学基金(1606RJZH153)

更新日期/Last Update:

2019-02-28